Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation.
Two patients with long-standing idiopathic chronic constipation, which responded only to large daily doses of laxatives and additional suppositories and enemas, were treated with the specific opioid antagonist, naloxone, on a single-blind crossover basis. Both patients responded to naloxone treatment, with increased passage of faeces and increased wet and dry faecal weight. Although naloxone is poorly absorbed after oral administration, there was a positive response during oral as well as intravenous treatment, suggesting that the primary effect of naloxone is at specific opiate receptor sites in the myenteric plexus and other neural and endocrine cells of the intestinal wall.
D000284:Administration, Oral; D000328:Adult; D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos; D011957:Receptors, Opioid
D010919:Placebos; D011957:Receptors, Opioid; D009270:Naloxone